Interim report into Gilenya safety released
Interim report into Gilenya safety released
Once-daily Gilenya therapy is effective after four years of real-world clinical use among patients with relapsing remitting multiple sclerosis (RRMS), and has a safety profile that is “broadly consistent” with that identified in clinical trials, according to an interim analysis from the PANGAEA long-term safety, tolerability, and effectiveness non-interventional study, presented at the 68th annual American Academy of Neurology meeting...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1416 Views
-
Last post by frodo
-
- 0 Replies
- 2232 Views
-
Last post by NHE
-
- 0 Replies
- 1755 Views
-
Last post by Tif
-
- 5 Replies
- 14863 Views
-
Last post by gibbledygook